According to the recent report by Grant Thornton Bharat, the Indian pharmaceutical and healthcare sector has encountered a wave in activity during the second trimester of calendar 2024, with 55 pacts totalling $4.1 billion. According to Grant Thornton Bharat’s report, notations a 57% increment in pact values parallel to the same period last year and an 8 times escalation from the previous trimester.
The average pact size also saw a rise, increasing from $9.7 million in the first quarter calendar year 2024 to $74 million in the second quarter 2024. This can be imputed to an increase in high-value pacts, with 11 pacts rising $3.4 billion compared to the last deal in the previous quarter.
Mergers and acquisitions (M&A) in the second quarter of 2024 captured an impressive 3.8 times rise in values, attaining $1.4 billion, while the volume of pacts increased by 29%. Dr Reddy’s Laboratories’ acquisition of Northstar Switzerland SARL for $633 million was the most important M&A transaction, pointing to the sector’s expanding global footprint.
Read About: Rajasthan Budget 2024 for Health Sector
The health tech and medical devices segments have seen a rise in investor wants, contributing to the overall pact value. Healthism MedTech’s acquisition by KKR Asian Fund IV, valued at $843 million, stands apart as the biggest pact of the quarter. Pacts volumes also experience a similar growth trajectory, with a 49% rise from 37 pacts in the second quarter of 2023 to 55 pacts in the second quarter of 2024.